Back to Search
Start Over
HER2-positive DTCs/CTCs in breast cancer.
- Source :
-
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer [Recent Results Cancer Res] 2012; Vol. 195, pp. 203-15. - Publication Year :
- 2012
-
Abstract
- The presence of circulating tumor cells (CTCs) in the blood as well as disseminated tumor cells (DTCs) in the bone marrow of breast cancer patients is associated with a worsened prognosis in the primary as well as in the metastatic situation. Next to their detection, evaluation of human epidermal growth factor receptor (HER2) expression is a valuable feature of CTCs/DTCs. As the HER2 status may change during disease progression CTCs/DTCs might (1) characterize the phenotype of minimal residual disease in the adjuvant setting and (2) serve as a "real time biopsy" of metastatic breast cancer. Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified.
Details
- Language :
- English
- ISSN :
- 0080-0015
- Volume :
- 195
- Database :
- MEDLINE
- Journal :
- Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
- Publication Type :
- Academic Journal
- Accession number :
- 22527508
- Full Text :
- https://doi.org/10.1007/978-3-642-28160-0_19